Medicines Optimisation - extracting the last vestiges of value from your medicines by Breen, Liz
The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Citation: Breen L (2016) Medicines Optimisation - extracting the last vestiges of value from your 
medicines. Journal of Medicines Optimisation. 2(3): 46-49. 
Copyright statement: © 2016 Pharman Limited. Full-text reproduced with publisher permission. 
Medicines Optimisation – extracting the last vestiges of value from your medicines. 
Dr Liz Breen, Senior Lecturer in Operations Management, Bradford University School of 
Management 
Correspondence to: l.breen@bradford.ac.uk  
 
Abstract 
 
Author list 
Breen L 
 
Summary 
The concept of waste and how it can be reduced, recycled, refurbished or reused in its current form 
has been widely discussed in industry. The importance of waste reduction from an environmental 
and economic perspective has also heightened in both industry and within the research arena. Thus 
said, stringent steps have been taken to facilitate the collection of and capture residual value in 
waste items. This article explores this premise in relation to medicines waste as part of the wider 
medicines optimisation agenda.  
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Medicines optimisation is about patients 
 
We are all very aware of what medicines optimisation is and what it aims to achieve. 
Medicines optimisation is about ensuring that the right patients get the right choice of 
medicine, at the right time. By focusing on patients and their experiences, the goal is to help 
patients to: improve their outcomes; take their medicines correctly; avoid taking 
unnecessary medicines; reduce wastage of medicines; and improve medicines safety.1  
 
The amount of medicines in the supply chain is increasing 
 
Medicines optimisation aims to get the most from medicines for both patients and the NHS 
due to the increase in people are taking more medicines.2 Evidence would suggest that we 
are living longer, living better and thus need more medication to sustain this, leading to an 
increase in polypharmacy. The output of which is an increase in the demand for 
pharmaceutical products which in turn increases the quantity of medicines in circulation; on 
manufacturer sites, wholesalers, pharmacies, and in patients’ homes.  
As stipulated by the Royal Pharmaceutical Society, Medicines Optimisation aims to deliver 
to its core principles: 1) aim to understand the patient’s experience; 2) evidence based 
choice of medicines; 3) ensure medicines use is as safe as possible; and 4) make medicines 
optimisation part of routine practice. If the principles are adopted and measurement and 
monitoring takes place then there should be improved patient outcomes3. This short 
perspective piece will reflect on and offer an alternative perspective on the third aim of this 
agenda focusing on medicines use safety. 
 
Medicine optimisation needs to encompass waste in the supply chain 
 
A basic business definition of Optimisation is; “Finding an alternative with the most cost 
effective or highest achievable performance under the given constraints, by maximizing 
desired factors and minimizing undesired ones”4 Medicines Optimisation as practiced does 
not ‘fit’ with this definition. It does not seek to consider alternatives at the point of 
dispensing. Pharmacists as experts in medicine, and in conjunction with learned 
professionals, seek to choose the right medicine, for the right treatment to ensure efficacy 
and effectiveness a positive clinical outcome and patient experience. To this end, the 
majority of activity and research in this area has considered the optimisation of medicines 
for the patient and less of the total optimisation of the product itself. Yet there are recent 
studies focusing on medicines further downstream in the supply chain e.g. waste 
management in pharmacies5  and care homes6 7, which is warranted as there is evidence of 
medicines stockpiling and greater vigilance should be paid to materials 
management/inventory control. The drivers of which are both cost reductions but also risk 
removal/minimisation.  
 
Medicines recovery – by hook or by crook, by truck or by foot? 
When considering the current medicines optimisation focus and efforts the following 
questions can be posited: 
1. Where is the focus on the safety of the patient and risk to the patient once they have 
medication in their possession and do not use it?  
2. How actively does the NHS system facilitate the recovery of unused medications?  
There is limited exploration of the recovery of unused and unwanted medications from 
patients, and even less into the mechanism by which they can be retrieved. Studies 
undertaken have examined why medicines recovery and analysis is undertaken in hospital 
pharmacies and has also highlighted deficiencies in the logistics infrastructure supporting 
medicines retrieval, for example whilst there is a clear legal impetus for collecting batteries 
for example the same driver does not exist for medicines8 9. 
The question must therefore be asked why we need to retrieve medicines in the first place. 
Surely once they are in the hands of the patients then the patient will know how to take 
them and how to dispose of them if they are surplus to requirements or they need to stop 
them as a course of treatment (due to side effects, efficacy issues etc.) There are 2 key 
benefits to retrieving medicines from patients: 
1. Reduction of hazards within the domestic environment due to medicines stockpiling 
(these can be accessed and misused by children or the elderly leading to hospital 
admissions or worse) 
2. The information that can be gleaned from the medicines themselves (prescribing 
source, contents, quantity, patient information leaflet and outer packaging) and 
their use (from patient’s consultations during and post treatment) when returning 
medicines. 
From a medicines optimisation perspective much can be learned from and acted upon 
from returned products to improve patient care and the processing of medicines from 
GPs/doctors to pharmacy and onto patients. 
  
What else can be done to improve recovery rates? 
The current medicines recovery system only works effectively if patients return medicines to 
community pharmacies, so is innately flawed by design as some patients may never choose 
to do this. As stated by the RPS, medicines optimisation can help encourage patients to take 
ownership of their treatment but this doesn’t automatically extend to ownership of and 
responsibility for product returns. Medicines need to be removed from patients’ homes and 
patients should have the option to: A) bring them back to a pharmacy or B) have them 
collected from their home/drop them at a collection point within their community. Both 
returns channels can be designed and executed to ensure optimal medicines are returned to 
community pharmacies.  
Option A - Patient education10, medicines take back schemes e.g. DUMP and re-ordering 
schemes e.g. Only Order What You Need11, and Pharmacist consultations can all play a 
strong role in developing ‘green consciousness’ to influence returns. The role of Community 
Pharmacy in facilitating this is tantamount to success and this is discussed in more detail 
below.  
 Option B - what can the NHS as a service do to improve recovery rates and move the 
emphasis from patient responsibility to system responsibility in recovering unwanted 
medications? Our American counterparts have over the years offered various solutions to 1) 
increase the ‘claw back’ of unused medicines  via street/domestic refuse collections and 2) 
reduce the risk to animals and people who may access medications that have been put into 
domestic waste (advocating mixing of medicines with undesirable products such as strong 
coffee or cat litter).  
Is this practice something that could be adopted as an extension of Medicines Optimisation 
in the NHS (UK)? Having consulted with local recycling depots the answer theoretically is 
yes. There is a well-established domestic refuse collection in place throughout the UK and 
strategically placed recycling centres so why can’t these be utilised to accept medicines (if 
placed in appropriately secure containers) and bring them to recycling sites to be disposed 
of as per safety regulations or handed over to a 3rd party for incineration. Collaborations of 
this ilk (NHS and local council waste management services) do exist but medicines are not 
included in this service12 . There is of course a cost to this system, but is the issue of 
medicines recovery and the risk to the patient of enough importance to warrant examining 
the feasibility of using such a system? 
 
Medicines information – and no, not the dial up kind 
There is a wealth of data sources that can be accessed to support medicines optimisation, 
from dashboards, to medication error reports, thermometers through to data mining and 
BIG DATA analysis (which allows NHS professionals to analyse huge quantities of data, 
identify trends and patterns to support the case for change and development). However, 
important data is at our fingertips when medicines are returned and is barely ever accessed 
or used in an informed manner. Medications once returned are destroyed as per regulations 
working on the assumption that as an end of life product they have no further value to offer 
so incineration is the next step. This isn’t so. The data that can be retrieved from a product 
once returned can inform GPs, pharmacists, service improvement managers, commissioners 
to name a few parties,  how effective prescribing is (how much has been prescribed, to 
whom and when it was dispensed). This can offer excellent data on medicines returned to 
pharmacy which can be used to inform improvement. Why do we not avail of this aspect of 
medicines optimisation? It is the final value added contribution of any medicinal product but 
it goes unnoticed.  The information is out there but worthless if the medication is not 
recovered.  
 
Community Pharmacy – can we do more?   
Community Pharmacy has a pivotal role to play in supporting and delivering to the 
medicines optimisation agenda, due to their proximity to their patients. Their intervention 
can be twofold: 1) medicines counselling and 2) medicines auditing.  
1) Community Pharmacists can work with patients or patient advocates and patient forums 
(e.g. GP surgery patient participation groups and CCG health forum participants) to counsel 
and educate on medicines use and re-ordering but also promote the retrieval of products. 
This practice can also be supplemented by one to one discussions with patients to learn 
more about their experience with their medicines (knowledge and comprehension of 
treatment, medicines compliance, storage, side effects, and disposal methods). This could 
be tied into MURs or be a separate consultation and could be especially beneficial to 
polypharmacy. The value of direct patient feedback can be extremely high if steps are taken 
to collate it in a manner which is user-friendly and accessible to the patient. Consultations in 
a community pharmacy setting would facilitate this.  
2) Patients should also be encouraged by their pharmacist (hospital and community) to 
return any waste medicines (by displaying promotional information on televisions, 
computer screens, posters, leaflets, stamps/logos on paper bags or by word of mouth). 
Once medicines are retrieved pharmacy staff should take advantage of the residual 
information held by said products and undertake regular audits or returned goods to 
feedback to local prescribing networks and other relevant parties. 
The introduction of such auditing practice can act as an early warning system for issues 
associated with poor prescribing practice, errors, counterfeit medication; some of which 
may not be picked up by patients until a red flag is triggered or illness/death occurs. Such 
analysis can also provide information to bodies such as the MHRA, NHS England, 
Department of Health and manufacturers on compliance issues, escalating returns of a 
specific product or serious near miss issues with medicinal products.    
Auditing practice can be cumulative when enough stock has been returned to warrant it 
(e.g. the bin is full) or cyclical (the stock is emptied and evaluated every day, week etc). 
Research in hospital pharmacies has shown that the practice of medicines audits and 
associated analysis can vary in relation to the practice and resources deployed to undertake 
this, from individual members of staff to dedicated teams5. Community pharmacies should 
determine the most sustainable method of undertaking a regular auditing system and 
resource this accordingly.  
 
Striding forward with purpose! 
Medicines optimisation is optimisation to the end of life, not the end of use. The focus 
currently seems to dwell on the optimal effectiveness of medicines dispensing and use but 
not on the whole life cycle of the product. Optimisation should consider the value of the 
pharmaceutical product once recovered from the patient and should encourage and 
facilitate this by enhanced retrieval systems. Pharmacy within the NHS underpins the 
success of medicines optimisation and thus needs to be able to do this effectively. This will 
impact on system design, workload planning, skills development and operational strategy 
and ultimately influence the constitution of pharmacy contracts. As asserted in the opening 
statement of this article, medicines optimisation is about ensuring that the right patients get 
the right choice of medicine, at the right time.  Pharmacy has made great strides to make 
this happen but can also use the strength and expertise of its staff to perfect and 
consistently optimise upon the use of medicines, active and waste medicines, within our 
healthcare system. This is an opportunity to do just this.   
Medicines optimisation needs to extend to the end of the pharmaceutical supply chain and 
that is final recovery and safe disposal of the product. Out of sight and out of mind cannot 
be how medicines are in patient’s homes. The safety of medicines use is key but the safety 
of the patient in the presence of medication is king.   
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